Intranasal
desmopressin (IN-
DDAVP) is used for home treatment of
menorrhagia in women with inherited
bleeding disorders. The effect of IN-
DDAVP on laboratory haemostatic parameters in women with
menorrhagia related to platelet dysfunction is unknown. We evaluated the effects of IN-
DDAVP on haemostatic parameters in women with
menorrhagia and platelet dysfunction and correlated them with menstrual flow. Eleven women (aged 18-45) with
menorrhagia and haemostatic abnormalities had determination of
von Willebrand factor antigen (VWF:Ag),
von Willebrand factor ristocetin cofactor (VWF:RCo) activity,
factor VIII coagulant activity (FVIII:C), platelet aggregation and platelet
adenosine tri-
phosphate (
ATP) release pre-IN-
DDAVP and 60-min post-IN-
DDAVP. Eight of eleven women underwent platelet function analyzer (PFA-100) closure time determination with
collagen/
adrenaline and
collagen/
adenosine diphosphate cartridges pretreatment and post-treatment. IN-
DDAVP was administered during two consecutive menstrual cycles. Menstrual flow was assessed during each cycle using a pictorial blood assessment chart. Treatment with IN-
DDAVP resulted in elevated VWF levels and shortened PFA-100 closure time with significant inverse correlation between shortening of PFA-100 closure times and increases in VWF levels. There were also significant inverse correlations between changes in menstrual flow and changes in VWF:Ag (P = 0.02), VWF:RCo (P = 0.04) and FVIII:C (P = 0.006), following treatment. In vitro platelet aggregation and platelet
ATP release response did not correct and did not correlate with changes in menstrual flow. Our results demonstrate a correlation between haemostatic parameters and menstrual flow following IN-
DDAVP in women with
menorrhagia and platelet dysfunction.